

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/
Form 8-K
June 12, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED):

JUNE 10, 2002

ANTIGENICS INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

000-29089
(COMMISSION FILE NUMBER)

06-15624
(I.R.S. EMPLOYER IDENTIFICATION NUMBER)

630 FIFTH STREET, SUITE 2100
NEW YORK, NEW YORK 10111
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE)

(212) 332-4774
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

ITEM 5. OTHER EVENTS.

Samuel D. Waksal, Ph.D. resigned from the Board of Directors of the Registrant effective June 10, 2002.

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: June 10, 2002

By: /s/ Garo H. Armen, Ph.D.

Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer